Drug Shortage Report for TRAVASOL
Report ID | 145280 |
Drug Identification Number | 00872296 |
Brand name | TRAVASOL |
Common or Proper name | TRAVASOL Amino acids (Blend C) injection |
Company Name | BAXTER CORPORATION |
Market Status | MARKETED |
Active Ingredient(s) | LEUCINE SERINE TYROSINE PROLINE ARGININE GLYCINE L-ALANINE TRYPTOPHAN THREONINE HISTIDINE VALINE ISOLEUCINE L-LYSINE METHIONINE PHENYLALANINE |
Strength(s) | 730MG 500MG 40MG 680MG 1.15G 1.03G 2.07G 180MG 420MG 480MG 580MG 600MG 580MG 400MG 560MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 3000 mL (JB6583) |
ATC code | B05BA |
ATC description | I.V. SOLUTIONS |
Reason for shortage | Shortage of an active ingredient. |
Anticipated start date | 2021-09-07 |
Actual start date | 2021-09-07 |
Estimated end date | |
Actual end date | 2021-10-01 |
Shortage status | Resolved |
Updated date | 2021-10-02 |
Company comments | Baxter is experiencing a delay in raw materials which has resulted in a supply disruption on certain CLINIMIX and TRAVASOL products. Impacted products have been placed on allocation. The supply issue is expected to be resolved in early October. Contact your Baxter sales rep or Baxter customer service for list of available CLINIMIX products which remain available to order. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 7125 MISSISSAUGA ROAD MISSISSAUGA, ONTARIO CANADA L5N 0C2 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2021-09-07 | English | Compare |
v2 | 2021-09-07 | French | Compare |
v3 | 2021-09-08 | English | Compare |
v4 | 2021-10-01 | English | Compare |
v5 | 2021-10-01 | French | Compare |
v6 | 2021-10-02 | English | Compare |
Showing 1 to 6 of 6